Early IVIg boost may tame muscle disease before it disables
NCT ID NCT05832034
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to better improvement than steroids alone. Myositis causes muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past year with certain types of myositis. Researchers measure muscle strength and disease activity after 12 weeks to see if the combination therapy works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Neurology, Amsterdam UMC, location AMC
Amsterdam, North Holland, 1105 AZ, Netherlands
Conditions
Explore the condition pages connected to this study.